- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02698462
Adding Family History of Colorectal Cancer to the Dutch FIT-based Screening Program
Adding Family History of Colorectal Cancer to the FIT-based Screening Program in a Dutch Colorectal Cancer Population Sample
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective CRC population-based screening trial, using FIT and a family history questionnaire, inviting those with a positive FIT, a familial CRC syndrome, or both for colonoscopy.
All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
The investigators will compare the diagnostic yield, participation rate, and positive predictive value for two strategies: referral for colonoscopy based on FIT and family history versus referral for colonoscopy based on FIT-only.
The sample size is justified by the anticipated gain in diagnostic yield from combining FIT-only with family history screening. With a sample size of 6.000 persons the investigators expect to detect 130 persons with advanced neoplasia after a positive FIT (21.7 per 1.000 invitees). By adding the family history questionnaire, the investigators anticipate detecting an additional number of 11 persons with advanced neoplasia, resulting in a yield of combined FIT-based and family history screening of 141 persons with advanced neoplasia (23.5 per 1.000 invitees), which is an increase of 1.8 per 1.000 invitees. Using the McNemar test with the significance level set at 5%, there is a power of 91% to show that the gain in diagnostic yield is statistically significant. Previous CRC test screening studies using FIT showed that participation rates are approximately 60% in a first screening round. The participation rate in the Dutch national CRC screening in 2014 (the first year of introduction) was even higher, 68%. The investigators expect that 80% of these persons will fill out the familial risk questionnaire, resulting in 3.264 persons who perform both tests. As the investigators recommend invitees to perform the questionnaire in addition to FIT, the investigators assume that the percentage of persons only filling out the questionnaire and not performing FIT are negligible. Based on previous screening studies using a FIT positivity cut-off value of 50 ng Hb/mL for the OC-Sensor, it is assumed that 8% of these participants have a positive FIT result. In the current Dutch screening program, a different FIT is used (FOB-Gold) with a cut-off value of 275 ng Hb/ml. The FIT positivity rate with this test and with this cut-off value is unknown. However, a governmental announcement recently reported that the positivity rate is expected to remain 8% with this cut-off value. Therefore, the investigators expect 326 FIT positives in this study (8% of 4.080). Based on previous studies, approximately 40% of all persons with a positive FIT result will have advanced neoplasia. In our sample this concerns 130 persons. The percentage of persons with a familial CRC risk requiring surveillance colonoscopies in a screening population varies between 2.3% and 4%. Differences in the definition of an increased familial CRC risk could explain the variability in reported numbers. As the investigators are using a relatively large range in criteria for fulfilling the definition of a familial CRC risk, the highest reported percentage (4%) is assumed, which concerns 131 persons. The previously developed family history questionnaire has a sensitivity of 90% and 100% in identifying those persons qualifying for referral, in two subsequent validation phases respectively. For the purpose of this study, this validated questionnaire is adjusted to the recently renewed referral criteria. The investigators make the assumption that the questionnaire can identify all persons with a familial CRC syndrome based on referral criteria. Persons with a familial CRC syndrome who do not fulfill these criteria will be missed. This concerns an unknown number and will not be taken into account. A previous screening study showed that 6% of those with a positive FIT have an increased familial CRC risk. One can calculate that 3.8% of persons with a negative FIT have a familial CRC risk: 4% minus 6% of 8% (FIT positives), divided by 92% (FIT negatives). If one assumes that there is no difference in familial CRC risk between those who do and those who do not fill out the questionnaire, this involves 114 of 3.264 persons. Based on unpublished data by this research group it is estimated that 10% of those with a negative FIT have a familial CRC risk: 11 persons (10% of 114). A similar percentage was found in another screening study. Additionally, all participants with a familial CRC syndrome will be offered surveillance recommendations. In this sample, 131 persons are estimated to have a familial CRC syndrome. Of these, 16 persons (12%) will undergo a colonoscopy due to a positive FIT (6% of 8% FIT positives) and their familial CRC risk could be addressed at their visit to a colonoscopy center. The other 115 persons (88%) are expected to have a negative FIT and these persons (and their family members) would otherwise be unlikely to be identified as having a familial CRC syndrome.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Six thousand persons eligible for the national CRC screening program, consisting of persons from the birth years 1941, 1945, 1953, 1955 and 1957 will be selected. These persons will be selected from four areas in North-Holland that are considered representative of the Netherlands regarding ethnical distribution and socioeconomic status: Aalsmeer, De Ronden Venen, Ouder-Amstel, Stichtse Vecht. These areas had an average participation-rate in 2014 that was comparable to the national participation rate (68.2%; a range from 65% to 75% is allowed). The distribution of age groups and gender will be comparable to the national screening distribution in 2016. Those who have been invited for a previous screening round in 2014 or for previous pilot-screening rounds will not be selected. In order to be eligible for participation, a subject must have been selected for participation in the national FIT-screening program in 2016.
Exclusion Criteria:
No specific exclusion criteria apply for participation in Family Matters, meaning that all invitees will receive a FIT as well as the questionnaire.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: FIT and Questionnaire
Six thousand persons eligible for the national CRC screening program will be selected.
They will be selected from four areas that are considered representative of the Netherlands.
All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire.
Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC.
Invitees are invited to perform both tests, but if they only perform one this will be assessed.
Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
|
All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire.
Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC.
Invitees are invited to perform both tests, but if they only perform one this will be assessed.
Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic yield
Time Frame: 1.5 years
|
number of participants in whom advanced neoplasia is detected relative to the number of invitees
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation rate
Time Frame: 1.5 years
|
Number of invitees completing the screening tests relative to the number of invitees
|
1.5 years
|
|
Positive predictive value
Time Frame: 1.5 years
|
Number of participants in whom advanced neoplasia is detected, relative to the number of participants testing positive
|
1.5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of invitees with a familial CRC syndrome
Time Frame: 1.5 years
|
1.5 years
|
|
|
FIT result of participants with a familial CRC syndrome
Time Frame: 1.5 years
|
1.5 years
|
|
|
The number of family members of participants with a familial CRC syndrome who receive an advice for genetic testing and/or surveillance colonoscopies
Time Frame: 1.5 years
|
1.5 years
|
|
|
The number of questionnaire participants who need help completing the questionnaire
Time Frame: 1.5 years
|
1.5 years
|
|
|
The number of persons with a positive questionnaire with a confirmed familial CRC syndrome
Time Frame: 1.5 years
|
1.5 years
|
|
|
The number of persons with a false-positive questionnaire as confirmed when verifying the completed questionnaire
Time Frame: 1.5 years
|
1.5 years
|
|
|
The number of persons with a false-negative questionnaire as confirmed when verifying the completed questionnaire in a random sample of those with a negative questionnaire
Time Frame: 1.5 years
|
1.5 years
|
|
|
Attendance rate to the intake visit at the department of clinical genetics
Time Frame: 1.5 years
|
1.5 years
|
|
|
Reasons for non-participation to genetic testing after a familial CRC risk
Time Frame: 1.5 years
|
This will be analyzed in a telephone interview
|
1.5 years
|
|
Attendance rate to the pre-colonoscopy consultation after a positive FIT or a familial CRC syndrome
Time Frame: 1.5 years
|
1.5 years
|
|
|
Reasons for non-participation to colonoscopy after a positive FIT or a familial CRC syndrome
Time Frame: 1.5 years
|
This will be analyzed in a telephone interview
|
1.5 years
|
|
The number of persons with non-advanced lesions (SSA/P, hyperplastic polyps, non-advanced adenomas) after a positive FIT or a familial CRC syndrome
Time Frame: 1.5 years
|
1.5 years
|
|
|
Comparison of diagnostic yield in detecting advanced neoplasia of FIT with the national CRC screening yield
Time Frame: 1.5 years
|
1.5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Evelien Dekker, MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 821748-140305-PG
- TC 12-05 (Other Grant/Funding Number: Dutch Digestive Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeWithdrawnColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
Bristol-Myers SquibbNovartisCompletedColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaUnited States, Canada, Spain, Argentina, Australia, Belgium, Czechia, Italy, Chile, Germany
-
University of ChicagoVerastem, Inc.SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditionsUnited States, Italy, China, Spain, Japan
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
Clinical Trials on Family history questionnaire
-
Fondazione Policlinico Universitario Campus Bio-MedicoIRCCS San Raffaele; A.O.U. Città della Salute e della Scienza - Molinette HospitalRecruitingNon Small Cell Lung CancerItaly
-
Federal State Budget Institution Research Center...Recruiting
-
Brigham and Women's HospitalBaylor College of Medicine; Duke University; National Human Genome Research Institute...CompletedHealthy Adults (Full Study and Extension Phase) | Hypertrophic Cardiomyopathy or Dilated CardiomyopathyUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedPediatric or Young Adult Cancer SurvivorsUnited States
-
Montclair State UniversityCompletedGenetic Predisposition | Genetic Hypertension
-
Brigham and Women's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedGenetic Predisposition to Disease | Hereditary DiseaseUnited States
-
State University of New York at BuffaloCompleted
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
VA Office of Research and DevelopmentCompletedColorectal CancerUnited States
-
Peking University Third HospitalRecruitingOvarian NeoplasmsChina